{"id":"torsemide-tablets-and-spironolactone-tablets","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Hypokalemia"},{"rate":"5-10%","effect":"Hyponatremia"},{"rate":"5-10%","effect":"Dehydration"},{"rate":"5-10%","effect":"Dizziness"},{"rate":"5-10%","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL1148","moleculeType":"Small molecule","molecularWeight":"348.43"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Torsemide's mechanism of action is similar to that of other thiazide-like diuretics, such as hydrochlorothiazide. However, torsemide has a more potent diuretic effect and a longer duration of action. Spironolactone's mechanism of action is unique among diuretics, as it works by antagonizing the mineralocorticoid receptor rather than inhibiting sodium reabsorption.","oneSentence":"Torsemide is a thiazide-like diuretic that works by inhibiting the sodium-chloride cotransporter in the distal convoluted tubule of the kidneys, leading to increased urine production and reduced fluid volume. Spironolactone is a potassium-sparing diuretic that works by antagonizing the mineralocorticoid receptor, leading to increased sodium excretion and reduced potassium loss.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:39:31.864Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Edema associated with congestive heart failure, cirrhosis of the liver, or a nephrotic syndrome in adults"},{"name":"Hypertension"}]},"trialDetails":[{"nctId":"NCT07046975","phase":"PHASE3","title":"Bioavailability and Bioequivalence Study of Extended Release Torsemide and Spironolactone","status":"COMPLETED","sponsor":"Sarfez Pharmaceuticals, Inc.","startDate":"2025-06-15","conditions":"Bioavailability Heathy Volunteers","enrollment":24},{"nctId":"NCT07223502","phase":"PHASE3","title":"A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease","status":"RECRUITING","sponsor":"Sarfez Pharmaceuticals, Inc.","startDate":"2025-12-01","conditions":"Hypertension (HTN)","enrollment":30},{"nctId":"NCT07015671","phase":"PHASE3","title":"Bioavailability and Bioequivalence Study of ER Torsemide and Spironolactone FDC Tablet in Healthy Subjects","status":"COMPLETED","sponsor":"Sarfez Pharmaceuticals, Inc.","startDate":"2025-07-01","conditions":"Bioequivalence Study in Healthy Subjects, PK/PD","enrollment":24},{"nctId":"NCT07043634","phase":"PHASE3","title":"A Study to Evaluate the Effect of Food or no Food on the Bioavailability of an Extended Release (ER) Torsemide and Spironolactone Fixed Dose Combination (FDC) Tablet in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Sarfez Pharmaceuticals, Inc.","startDate":"2025-06-15","conditions":"Bioavailability Heathy Volunteers","enrollment":24},{"nctId":"NCT06039592","phase":"","title":"Study of Innovative Drug Strategies in Improving Left Ventricular Function After Mitral Repair","status":"UNKNOWN","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2022-04-01","conditions":"Congenital Mitral Insufficiency","enrollment":164},{"nctId":"NCT06039540","phase":"","title":"Study of Drug Therapy for Pediatric Heart Failure","status":"UNKNOWN","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2022-01-01","conditions":"Heart Failure Congenital","enrollment":200},{"nctId":"NCT06037434","phase":"","title":"Study of Innovative Drug Treatment Therapy for Pediatric Mitral Regurgitation","status":"UNKNOWN","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2022-04-01","conditions":"Congenital Mitral Insufficiency","enrollment":122}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Torsemide Tablets and Spironolactone Tablets","genericName":"Torsemide Tablets and Spironolactone Tablets","companyName":"Sarfez Pharmaceuticals, Inc.","companyId":"sarfez-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Torsemide is a thiazide-like diuretic that works by inhibiting the sodium-chloride cotransporter in the distal convoluted tubule of the kidneys, leading to increased urine production and reduced fluid volume. Spironolactone is a potassium-sparing diuretic that works by antagonizing the mineralocorticoid receptor, leading to increased sodium excretion and reduced potassium loss. Used for Edema associated with congestive heart failure, cirrhosis of the liver, or a nephrotic syndrome in adults, Hypertension.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}